No 01 2025

The gala, organized by the Women in Business network, highlights female role models and works towards a more gender-equal corporate sector.

The FDA has approved the company’s IND application to initiate the Phase I/II study Oncorella-1.

The US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need.

Paxman has announced a recommended offer to the shareholders of Dignitana to transfer all shares issued by Dignitana to Paxman, against consideration in the form of a total of 2,476,207 newly issued shares in Paxman.

Ted Fjällman (TF), CEO of the Swedish listed investment company Flerie, and Tim Opler (TO), Managing Director of the global healthcare group at investment firm Stifel, both work with life science investments in Europe, the USA and globally. They share, in a conversation format, their thoughts about the financial landscape and the Nordic life science ecosystem.

The Court of Appeal has overturned the District Court’s acquittal in the insider trading case involving events from the spring of 2019 and individuals from the company’s former management.

The company has announced the authorization of its Clinical Trial Application (CTA) from the regulatory authorities in four European countries under the European Union’s (EU) harmonised framework, for VIDAR-1, with Germany acting as the reference state.